<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04469920</url>
  </required_header>
  <id_info>
    <org_study_id>SARO.19.003</org_study_id>
    <nct_id>NCT04469920</nct_id>
  </id_info>
  <brief_title>Hepatic Impairment, Cholestatic Liver Disease, &amp; NASH With Advanced Fibrosis &amp; Normal Hepatic Function</brief_title>
  <official_title>Evaluation of Pharmacokinetics and Safety of Saroglitazar Magnesium in Participants With Normal Hepatic Function and With Hepatic Impairment, Cholestatic Liver Disease, NASH With Advanced Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zydus Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zydus Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a Phase 1, Open-label Study of Participants with Hepatic Impairment, Cholestatic&#xD;
      Liver Disease, and NASH with Advanced Fibrosis and Normal Hepatic Function&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Male and female participants 18-80 years of age (inclusive) with normal hepatic function or&#xD;
      hepatic impairment/disease who meet all of the inclusion and none of the exclusion criteria.&#xD;
      Subjects with hepatic impairment will be enrolled based upon the Child-Pugh-Turcotte (CPT)&#xD;
      classification system for mild hepatic impairment (Group 1 CPT Class A without PHT; Group 2&#xD;
      CPT Class A with PHT), moderate hepatic impairment (Group 3 Decompensated CPT Class B), or&#xD;
      severe hepatic impairment (Group 4 Decompensated CPT Class C). Group 5 will include subjects&#xD;
      with cholestatic liver disease and Group 6 will include subjects with non-cirrhotic advanced&#xD;
      fibrosis secondary to NASH (non-alcoholic steatohepatitis). The control group (Group 7) will&#xD;
      consist of demographic matched subjects with normal hepatic function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2020</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC from time zero to infinity (AUC0-∞)</measure>
    <time_frame>Before dosing on Day 1 through Day 7</time_frame>
    <description>The area under the plasma concentration versus time curve from zero to infinity will be calculated by adding Ct/Kel to AUCt, where Ct is the last quantifiable concentration and Kel is the elimination rate constant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time zero to the last quantifiable concentration (AUC0-t)</measure>
    <time_frame>Before dosing on Day 1 through Day 7</time_frame>
    <description>The area under the plasma concentration versus time curve will be calculated using the linear trapezoidal rule from the zero time point to the last quantifiable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Before dosing on Day 1 through Day 7</time_frame>
    <description>Maximum measured plasma concentration over the time span specified.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Before dosing on Day 1 through Day 7</time_frame>
    <description>Time of the maximum measured plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2</measure>
    <time_frame>Before dosing on Day 1 through Day 7</time_frame>
    <description>The half-life will be calculated by the equation tHalf = 0.693/ Kel. Kel (The terminal elimination rate constant) will be obtained from the slope of the line, fitted by linear least squares regression, through the terminal points of the natural log of the concentration versus time plot for these points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F</measure>
    <time_frame>Before dosing on Day 1 through Day 7</time_frame>
    <description>Clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F</measure>
    <time_frame>Before dosing on Day 1 through Day 7</time_frame>
    <description>Volume of distribution</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine Pharmacokinetic: Ae</measure>
    <time_frame>Before dosing on Day 1 through Day 5</time_frame>
    <description>Amount of drug excreted during each collection interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs</measure>
    <time_frame>Before dosing on Day 1 through Day 12</time_frame>
    <description>Incidence and severity of AEs as a measure of safety and tolerability will be measured and reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unbound Fraction</measure>
    <time_frame>Day 1</time_frame>
    <description>Unbound fraction in plasma of Saroglitazar</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unbound concentration</measure>
    <time_frame>Day 1</time_frame>
    <description>Unbound concentration in plasma of Saroglitazar</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Group 1- mild hepatic impairment without evidence of PHT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject with mild hepatic impairment without evidence of portal hypertension (PHT) based on Class A CPT score 5-6 points</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2- mild hepatic impairment with evidence of PHT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with mild hepatic impairment with evidence of portal hypertension based on Class A CPT score 5-6 points</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3-moderate hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with moderate hepatic impairment based on Class B CPT score 7-9 points</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4- severe hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with severe hepatic impairment based on Class C CPT score 10-14 points)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5-cholestatic liver disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with cholestatic liver disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6-Non-cirrhotic Advanced Fibrosis secondary to NASH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with Non-cirrhotic Advanced Fibrosis secondary to NASH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7- normal hepatic function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with normal hepatic function</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saroglitazar Magnesium 2 mg</intervention_name>
    <description>1 tablet, single dose at Day 1</description>
    <arm_group_label>Group 5-cholestatic liver disease</arm_group_label>
    <arm_group_label>Group 6-Non-cirrhotic Advanced Fibrosis secondary to NASH</arm_group_label>
    <arm_group_label>Group 7- normal hepatic function</arm_group_label>
    <other_name>Not any</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saroglitazar Magnesium 4 mg</intervention_name>
    <description>1 tablet, single dose at Day 1</description>
    <arm_group_label>Group 1- mild hepatic impairment without evidence of PHT</arm_group_label>
    <arm_group_label>Group 2- mild hepatic impairment with evidence of PHT</arm_group_label>
    <arm_group_label>Group 3-moderate hepatic impairment</arm_group_label>
    <arm_group_label>Group 4- severe hepatic impairment</arm_group_label>
    <arm_group_label>Group 5-cholestatic liver disease</arm_group_label>
    <arm_group_label>Group 6-Non-cirrhotic Advanced Fibrosis secondary to NASH</arm_group_label>
    <arm_group_label>Group 7- normal hepatic function</arm_group_label>
    <other_name>Not any</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to comprehend and willingness to sign a written informed consent for the&#xD;
             study.&#xD;
&#xD;
          2. Male or female aged 18 to 80 years (inclusive) at the time of signing the ICF.&#xD;
&#xD;
          3. Body mass index within the range 18.0 to 48.0 kg/m2 (inclusive) at screening.&#xD;
&#xD;
          4. Females must be non-pregnant, non-lactating and of non-childbearing potential or using&#xD;
             highly efficient contraception for the full duration of the study.&#xD;
&#xD;
          5. Females of child-bearing potential and Males must agree to use contraception for the&#xD;
             full duration of the study.&#xD;
&#xD;
          6. Ability to swallow and retain oral medication.&#xD;
&#xD;
          7. Groups 1 through 6 subjects may have medical findings consistent with their degree of&#xD;
             hepatic dysfunction, as determined by medical history, physical examination, vital&#xD;
             signs, ECGs, and clinical laboratory examinations at screening and check-in.&#xD;
             Participants with abnormal findings considered not clinically significant by the&#xD;
             Investigator are eligible.&#xD;
&#xD;
          8. Participants with hepatic impairment in Groups 1-4 will be classified at screening&#xD;
             based on CPT score. If the hepatic impairment classification for the subject is not&#xD;
             the same at screening and day -1, enrolment of the subject into a hepatic category&#xD;
             group will be at the discretion of the hepatology Investigator.&#xD;
&#xD;
          9. Laboratory test values for Groups 1-4 hepatic impairment subjects must be clinically&#xD;
             acceptable to the Investigator and meet all of the following parameters at Screening:&#xD;
&#xD;
               1. ALT/AST value ≤ 10 × upper limit of normal (ULN)&#xD;
&#xD;
               2. Absolute neutrophil count (ANC) ≥ 750/mm3&#xD;
&#xD;
               3. Platelets ≥ 25,000/mm3&#xD;
&#xD;
               4. Hemoglobin ≥ 8 g/dL&#xD;
&#xD;
               5. α-fetoprotein &lt; 50 ng/mL or 50-80 ng/mL with concurrent negative imaging study&#xD;
                  (US, CT, MRI)&#xD;
&#xD;
         10. Group 2 must have evidence of PHT as manifested by one of the following:&#xD;
&#xD;
               1. presence of hepatic encephalopathy or ascites (on exam or imaging or medication&#xD;
                  to control these symptoms),&#xD;
&#xD;
               2. historical or current presence of varices by imaging or endoscopy,&#xD;
&#xD;
               3. historical or current presence of splenomegaly by imaging or physical exam,&#xD;
&#xD;
               4. previous Hepatic Venous Pressure Gradient Measurement (HVPG) &gt;10 mmHg,&#xD;
&#xD;
               5. platelet count &lt;150,000/mm3 (or /uL), or&#xD;
&#xD;
               6. Fibroscan® at screening &gt;20 kPa.&#xD;
&#xD;
         11. Documented history of cholestatic liver disease (i.e. primary biliary cholangitis,&#xD;
             primary sclerosing cholangitis) OR alkaline phosphatase at screening of &gt;1.25 x ULN&#xD;
             with AST/ALT &lt;1.2 x ULN OR Historical presence of AMA (anti-mitochondrial antibody)&#xD;
             &gt;1:40 and elevated alkaline phosphatase &gt; ULN at screening&#xD;
&#xD;
         12. Clinical diagnosis of NASH and the following criteria:&#xD;
&#xD;
             a. Screening Fibroscan® with liver stiffness &gt; 8.5 kPa AND CAP &gt;280 dB AND At least&#xD;
             two criteria for metabolic syndrome modified from the NCEP&#xD;
&#xD;
             ATP III Guidelines, at screening:&#xD;
&#xD;
             i. Fasting glucose &gt;100 mg/dL or receiving drug treatment for elevated glucose, ii.&#xD;
             Fasting HDL cholesterol &lt;40 mg/dL in men and &lt;50 mg/dL in women or receiving drug&#xD;
             treatment for low HDL cholesterol, iii. Fasting triglycerides &gt; 150 mg/dL or receiving&#xD;
             drug treatment for hypertriglyceridemia, iv. Waist circumference &gt;102 cm for men or&#xD;
             &gt;88 cm for women or BMI &gt;30 kg/m2, v. Systolic blood pressure &gt;130 mmHg or diastolic&#xD;
             blood pressure &gt;85 mmHg or receiving drug treatment for hypertension&#xD;
&#xD;
             OR:&#xD;
&#xD;
             b. A historical liver biopsy within 6 months of screening consistent with NASH with&#xD;
             stage 3 fibrosis and no documented weight loss &gt;10% since date of liver biopsy&#xD;
&#xD;
         13. Subjects with normal hepatic function must match in age (± 10 years), gender, and&#xD;
             weight (± 10 kg) with hepatic disease participants in the Groups 1-6.&#xD;
&#xD;
         14. Subjects should be in good health as determined by no clinically significant findings&#xD;
             in the medical history, physical examination, vital signs, 12-lead electrocardiograms&#xD;
             (ECGs), or laboratory examinations at Screening or Check-in.&#xD;
&#xD;
         15. Laboratory test values within normal limits or considered not clinically significant&#xD;
             by the Investigator for subjects with normal hepatic function including ALT/AST &lt; 1.2&#xD;
             × ULN at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any significant, unstable medical condition or other instability that would prevent&#xD;
             the subject from participating in the study as determined by the Investigator or&#xD;
             designee.&#xD;
&#xD;
          2. History of malignancy of any type in the last 3 years of screening, with the exception&#xD;
             of the following: in situ cervical or breast cancer or surgically excised non-melanoma&#xD;
             skin cancers (i.e. basal cell or squamous cell carcinoma).&#xD;
&#xD;
          3. History of stomach or intestinal surgery or resection within the six months prior to&#xD;
             screening that would potentially alter absorption and/or excretion of orally&#xD;
             administered drugs (uncomplicated appendectomy, cholecystectomy, and hernia repair&#xD;
             will be allowed).&#xD;
&#xD;
          4. History of any significant drug allergy (such as anaphylaxis) deemed clinically&#xD;
             relevant by the Investigator.&#xD;
&#xD;
          5. Any major surgery within 3 months of screening.&#xD;
&#xD;
          6. Donation of blood or blood products within 3 months prior to screening.&#xD;
&#xD;
          7. Current active infectious disease requiring systemic antibiotic, antifungal, or&#xD;
             antiviral treatment or symptoms of active infectious disease within the two weeks&#xD;
             prior to screening.&#xD;
&#xD;
          8. Use or intend to use any medications/products known to alter drug absorption,&#xD;
             metabolism, or elimination processes, including St. John's Wort, within 21 days prior&#xD;
             to screening, unless deemed acceptable by the Investigator.&#xD;
&#xD;
          9. Receiving or has received any investigational drug within the 30 days or 5 halflives&#xD;
             (whichever is longer), before receiving Saroglitazar Magnesium.&#xD;
&#xD;
         10. Estimated glomerular filtration rate (eGFR) &lt; 60 mL/min/1.73m2 by modification of diet&#xD;
             in renal disease (MDRD) formula at screening.&#xD;
&#xD;
         11. Positive alcohol breath test at the time of check-in or those subjects who have&#xD;
             current alcohol or substance abuse judged by the Investigator to potentially interfere&#xD;
             with subject compliance or subject safety.&#xD;
&#xD;
         12. Positive test for drugs of abuse at screening or admission.&#xD;
&#xD;
         13. Any subject with poor peripheral venous access&#xD;
&#xD;
         14. Receipt of blood products within 1 month prior to check in.&#xD;
&#xD;
         15. Human immunodeficiency virus (HIV) type 1 antibody positive at screening for all&#xD;
             groups.&#xD;
&#xD;
         16. Subjects who have had a change in hepatic disease status within 30 days of screening,&#xD;
             as documented by the participant's medical history and deemed clinically significant&#xD;
             by the Investigator.&#xD;
&#xD;
         17. Electrocardiogram QTcF &gt; 500 msec, confirmed by repeat measurement OR presence of&#xD;
             second- or third-degree atrioventricular (AV) block.&#xD;
&#xD;
         18. Subjects having -&#xD;
&#xD;
               1. History of gastrointestinal bleeding within 1 month prior to screening.&#xD;
&#xD;
               2. Current functioning organ transplant.&#xD;
&#xD;
               3. Evidence of severe ascites requiring frequent paracentesis in the opinion of&#xD;
                  investigator.&#xD;
&#xD;
         19. Subjects having a history of any of the following: hepatic encephalopathy, ascites,&#xD;
             history or current presence of varices by imaging or endoscopy, history or current&#xD;
             presence of splenomegaly by imaging or physical exam, previous HVPG &gt;10, platelet&#xD;
             count &lt;150,000 (or /uL) at screening, or Fibroscan® at screening &gt;20 kPa.&#xD;
&#xD;
         20. QT interval corrected for heart rate using Fridericia's method (QTcF) &gt; 450 msec,&#xD;
             confirmed by repeat measurement OR presence of second- or third-degree AV block.&#xD;
&#xD;
         21. Hepatitis B virus surface antigen (HBsAg) positive, Hepatitis C virus antibody&#xD;
             (HCV-Ab) positive.&#xD;
&#xD;
         22. Subjects who use or intend to use any over the counter (vitamins, minerals, and&#xD;
             phytotherapeutic/herbal/plant-derived preparations) or prescription medications within&#xD;
             30 days or 5 half-lives (whichever is longer) prior to enrolment, with the exception&#xD;
             of hormone replacement therapy and therapies for hepatic disease and treatments of&#xD;
             associated disorders that have been stable for at least 30 days prior to screening and&#xD;
             until Day 1, unless deemed acceptable by the Investigator (or designee).&#xD;
&#xD;
         23. Other known cause of liver disease such as NASH, Alcoholic Steatohepatitis (ASH),&#xD;
             autoimmune hepatitis, or acute or chronic viral hepatitis as determined by the&#xD;
             Investigator and subject's medical records&#xD;
&#xD;
         24. Evidence of liver decompensation such as ascites, hepatic encephalopathy or prior&#xD;
             history of variceal bleed.&#xD;
&#xD;
         25. No other known cause of liver disease such as Primary Biliary Cholangitis (PBC),&#xD;
             Primary Sclerosing Cholangitis (PSC), Alcoholic Steatohepatitis (ASH), autoimmune&#xD;
             hepatitis, or acute or chronic viral hepatitis as determined by the Investigator and&#xD;
             subject's medical records&#xD;
&#xD;
         26. Platelet count &lt;150,000 (or /uL)&#xD;
&#xD;
         27. Subjects who have taken any prescription medications or over-the-counter medications,&#xD;
             including herbal products, within 14 days prior to start of study drug dosing, with&#xD;
             the exception of vitamins, acetaminophen, hormonal contraceptive medications and/or&#xD;
             any other over-the-counter product approved by the Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deven Parmar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Zydus Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr. Deven V. Parmar, MD</last_name>
    <phone>+971-43998280</phone>
    <phone_ext>121</phone_ext>
    <email>deven.parmar@zydusdiscovery.ae</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr. Farheen A. Shaikh</last_name>
    <phone>+971-43998280</phone>
    <phone_ext>105</phone_ext>
    <email>Farheen.arifahmed@zydusdiscovery.ae</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raj Vuppalanchi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Raj Vuppalanchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Research Corporation at Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Lawitz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric Lawitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2023</verification_date>
  <study_first_submitted>July 9, 2020</study_first_submitted>
  <study_first_submitted_qc>July 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2020</study_first_posted>
  <last_update_submitted>August 6, 2023</last_update_submitted>
  <last_update_submitted_qc>August 6, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04469920
org study id: SARO.19.003
nct id: NCT04469920
lead sponsor: 
has dmc: No
is fda regulated drug: Yes
is fda regulated device: No
This will be a Phase 1, Open-label Study of Participants with Hepatic Impairment, Cholestatic
      Liver Disease, and NASH with Advanced Fibrosis and Normal Hepatic Function
Male and female participants 18-80 years of age (inclusive) with normal hepatic function or
      hepatic impairment/disease who meet all of the inclusion and none of the exclusion criteria.
      Subjects with hepatic impairment will be enrolled based upon the Child-Pugh-Turcotte (CPT)
      classification system for mild hepatic impairment (Group 1 CPT Class A without PHT; Group 2
      CPT Class A with PHT), moderate hepatic impairment (Group 3 Decompensated CPT Class B), or
      severe hepatic impairment (Group 4 Decompensated CPT Class C). Group 5 will include subjects
      with cholestatic liver disease and Group 6 will include subjects with non-cirrhotic advanced
      fibrosis secondary to NASH (non-alcoholic steatohepatitis). The control group (Group 7) will
      consist of demographic matched subjects with normal hepatic function.
allocation: Non-Randomized
intervention model: Parallel Assignment
primary purpose: Other
masking: None (Open Label)
measure: AUC from time zero to infinity (AUC0-∞)
time frame: Before dosing on Day 1 through Day 7
description: The area under the plasma concentration versus time curve from zero to infinity will be calculated by adding Ct/Kel to AUCt, where Ct is the last quantifiable concentration and Kel is the elimination rate constant.
measure: AUC from time zero to the last quantifiable concentration (AUC0-t)
time frame: Before dosing on Day 1 through Day 7
description: The area under the plasma concentration versus time curve will be calculated using the linear trapezoidal rule from the zero time point to the last quantifiable concentration.
measure: Cmax
time frame: Before dosing on Day 1 through Day 7
description: Maximum measured plasma concentration over the time span specified.
measure: Tmax
time frame: Before dosing on Day 1 through Day 7
description: Time of the maximum measured plasma concentration.
measure: t1/2
time frame: Before dosing on Day 1 through Day 7
description: The half-life will be calculated by the equation tHalf = 0.693/ Kel. Kel (The terminal elimination rate constant) will be obtained from the slope of the line, fitted by linear least squares regression, through the terminal points of the natural log of the concentration versus time plot for these points
measure: CL/F
time frame: Before dosing on Day 1 through Day 7
description: Clearance
measure: Vz/F
time frame: Before dosing on Day 1 through Day 7
description: Volume of distribution
measure: Urine Pharmacokinetic: Ae
time frame: Before dosing on Day 1 through Day 5
description: Amount of drug excreted during each collection interval
measure: Incidence of AEs
time frame: Before dosing on Day 1 through Day 12
description: Incidence and severity of AEs as a measure of safety and tolerability will be measured and reported.
measure: Unbound Fraction
time frame: Day 1
description: Unbound fraction in plasma of Saroglitazar
measure: Unbound concentration
time frame: Day 1
description: Unbound concentration in plasma of Saroglitazar
arm group label: Group 1- mild hepatic impairment without evidence of PHT
arm group type: Experimental
description: Subject with mild hepatic impairment without evidence of portal hypertension (PHT) based on Class A CPT score 5-6 points
arm group label: Group 2- mild hepatic impairment with evidence of PHT
arm group type: Experimental
description: Subjects with mild hepatic impairment with evidence of portal hypertension based on Class A CPT score 5-6 points
arm group label: Group 3-moderate hepatic impairment
arm group type: Experimental
description: Subjects with moderate hepatic impairment based on Class B CPT score 7-9 points
arm group label: Group 4- severe hepatic impairment
arm group type: Experimental
description: Subjects with severe hepatic impairment based on Class C CPT score 10-14 points)
arm group label: Group 5-cholestatic liver disease
arm group type: Experimental
description: Subjects with cholestatic liver disease
arm group label: Group 6-Non-cirrhotic Advanced Fibrosis secondary to NASH
arm group type: Experimental
description: Subjects with Non-cirrhotic Advanced Fibrosis secondary to NASH
arm group label: Group 7- normal hepatic function
arm group type: Experimental
description: Subjects with normal hepatic function
intervention type: Drug
intervention name: Saroglitazar Magnesium 2 mg
description: 1 tablet, single dose at Day 1
arm group label: Group 5-cholestatic liver disease
arm group label: Group 6-Non-cirrhotic Advanced Fibrosis secondary to NASH
arm group label: Group 7- normal hepatic function
other name: Not any
intervention type: Drug
intervention name: Saroglitazar Magnesium 4 mg
description: 1 tablet, single dose at Day 1
arm group label: Group 1- mild hepatic impairment without evidence of PHT
arm group label: Group 2- mild hepatic impairment with evidence of PHT
arm group label: Group 3-moderate hepatic impairment
arm group label: Group 4- severe hepatic impairment
arm group label: Group 5-cholestatic liver disease
arm group label: Group 6-Non-cirrhotic Advanced Fibrosis secondary to NASH
arm group label: Group 7- normal hepatic function
other name: Not any
criteria: 
gender: All
minimum age: 18 Years
maximum age: 80 Years
healthy volunteers: No
last name: Deven Parmar, MD
role: Study Director
affiliation: Zydus Therapeutics Inc.
last name: Dr. Deven V. Parmar, MD
phone: +971-43998280
phone ext: 121
email: deven.parmar@zydusdiscovery.ae
last name: Dr. Farheen A. Shaikh
phone: +971-43998280
phone ext: 105
email: Farheen.arifahmed@zydusdiscovery.ae
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
country: United States
responsible party type: Sponsor
mesh term: Liver Diseases
sharing ipd: No